<DOC>
	<DOC>NCT01788046</DOC>
	<brief_summary>This study is designed to assess the efficacy and safety of etelcalcetide (AMG 416) compared with placebo in the treatment of SHPT in CKD patients receiving hemodialysis.</brief_summary>
	<brief_title>Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<criteria>Subject understands the study procedures and agrees to participate in the study by giving written informed consent. Subject is 18 years of age or older. Subject agrees to not participate in another study of an investigational agent during the study. Subject must be receiving hemodialysis 3 times weekly for at least 3 months Other Inclusion Criteria may apply Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening. Other investigational procedures while participating in this study are excluded. Anticipated or scheduled parathyroidectomy during the study period. Subject has received a parathyroidectomy within 3 months prior to dosing. Anticipated or scheduled kidney transplant during the study period. Subject has known sensitivity to any of the products or components to be administered during dosing. Subject has participated in a prior clinical trial of AMG 416 Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator. Subject has a history of any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject. Other Exclusion Criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Secondary Hyperparathyroidism (SHPT), chronic kidney disease (CKD), hemodialysis, parathyroid hormone (PTH), hypocalcemia, bone and mineral metabolism</keyword>
</DOC>